Quick answer
Medically supervised GLP-1 weight loss in Bangkok means a licensed physician screens you for contraindications, orders baseline bloodwork, prescribes one of several GLP-1 medications matched to your profile, and reviews your response and labs on a set schedule. Outcomes vary between individuals, and this is not a substitute for individual medical advice.
At Healthi Life, the private longevity house in Ekkamai, Bangkok, GLP-1 weight loss is delivered as a physician-supervised program, not a standalone injection sold over a counter. This guide explains what "medically supervised" means in practice, how a physician chooses between the available GLP-1 options, what the first appointment involves, and how to decide which program page to start from. It sits within the metabolic and longevity programs supervised by Dr. Petch.
What "Medically Supervised" Means for GLP-1 Weight Loss
GLP-1 medications are prescription-only. That single fact shapes everything about how a responsible program is structured. Before any prescription is written, a physician reviews your medical history and current medications, then screens for contraindications, including a personal or family history of medullary thyroid carcinoma or MEN-2, pancreatitis, severe gastrointestinal disease, and pregnancy or breastfeeding.
Baseline biomarkers, such as HbA1c, a lipid panel, and hepatic and renal function, are established before the first dose. Once treatment starts, follow-up is monthly rather than one-and-done: your physician reviews side effects, checks how you are tolerating the medication, and adjusts the plan. This is what distinguishes physician-led care from an unsupervised purchase — the assessment does not stop after the first prescription.
How a Physician Chooses Between the GLP-1 Options
Several GLP-1 and related molecules are available, and they are not interchangeable. Ozempic and Wegovy both use semaglutide, a GLP-1 receptor agonist; Ozempic is the brand most associated with diabetes care, while Wegovy is the same molecule licensed specifically for weight management. Mounjaro uses tirzepatide, a dual GIP/GLP-1 agonist, and is approved for both type 2 diabetes and weight management. Retatrutide is a triple-receptor molecule that remains investigational and is offered strictly within a supervised research framework. At Healthi Life, only Mounjaro and retatrutide are prescribed; semaglutide (Ozempic / Wegovy) is not dispensed.
A physician weighs your medical history, contraindications, and goals against this profile, then recommends the option that fits — rather than defaulting to whichever is best known by name. Individual response to any of these medications varies, and the choice is revisited as your labs and tolerability come in.
"The molecule is not the starting point. The person is. We screen first, test first, and only then decide which GLP-1 option — if any — fits the picture in front of us."
What Happens at the First Appointment
The first visit is diagnostic, not transactional. It follows a structured path:
- Medical intake. A physician reviews your full history, current medications and goals, and screens for contraindications before anything is prescribed.
- Baseline biomarkers. HbA1c, lipid panel, and hepatic and renal function are established before the first dose.
- Molecule selection. The physician selects the GLP-1 option that fits your profile and confirms the starting dose and injection training.
- Monthly follow-up. Clinical review, side-effect assessment and biomarker follow-up happen on a set schedule, with dosing adjusted as needed.
Pricing for each option, including consultation and per-vial detail, is published transparently on the relevant service page and confirmed at your physician consultation — nothing here should be read as a quoted price.
Safety, Monitoring and What to Expect
Reported effects during titration commonly include nausea, decreased appetite, and gastrointestinal symptoms; less common but more serious risks, such as pancreatitis or gallbladder disease, are part of why contraindication screening and monthly review exist. None of this should be read as a promise of a particular result or a specific timeline. Outcomes vary between individuals, and a physician-supervised program is designed to catch and manage issues early rather than to guarantee an outcome.
This article does not replace individual medical advice. Whether GLP-1 therapy is appropriate for you, and which option if any, is confirmed only after your physician has reviewed your history and labs.
Which GLP-1 Program Fits You?
Each option below is a genuine prescription medicine with a different profile. Current pricing for each is listed on its own service page and confirmed at your physician consultation — figures are not repeated here.
- Medical Weight Loss Bangkok — the hub page to start from: compare Mounjaro and retatrutide, the two GLP-1 options prescribed at Healthi Life (semaglutide is shown as not dispensed), and book the consultation that determines eligibility.
- Ozempic Bangkok — what the semaglutide brand most associated with diabetes care is, and why Healthi Life does not dispense it.
- Wegovy Bangkok — the same semaglutide molecule licensed specifically for weight management; not dispensed at Healthi Life, with the prescribed alternatives and their prices.
- Mounjaro Bangkok — tirzepatide, acting on two incretin receptors, for guests whose physician wants dual GIP/GLP-1 action considered.
- Retatrutide Bangkok — an investigational triple-receptor molecule, offered only within a supervised research framework for eligible guests.
None of these pages substitute for the physician consultation. The right option, and whether GLP-1 therapy is appropriate at all, is confirmed by medical assessment.
GLP-1 Weight Loss Within a Longevity Strategy
A single prescription is a starting point. A longevity strategy is a system.
GLP-1 therapy is often most useful when coordinated with broader metabolic, hormone and biomarker-tracking programs, rather than treated as an isolated intervention. At Healthi Life, that coordination sits with the physician managing your program, who reviews labs alongside your wider health picture at each monthly visit.
That is the difference between a prescription and a strategy. On its own, a GLP-1 medication is a tool. Embedded in a physician-supervised plan with real monitoring, it becomes part of a measured, longer-term approach to metabolic health.
GLP-1 Weight Loss at Healthi Life
Medical weight loss is available at Healthi Life, the private longevity house in Ekkamai, Bangkok (94 Ekkamai 10).
- Program: Physician-prescribed GLP-1 therapy, under medical assessment
- Options at Healthi Life: Mounjaro (approved for weight management), Retatrutide (investigational). Semaglutide (Wegovy, Ozempic) is not dispensed
- Monitoring: Baseline and follow-up biomarkers, monthly physician review
- Supervised by: Dr. Sarassawadee Suwanjinda (Dr. Petch), Co-Founder & Chief Medical Officer
All treatment begins with physician assessment. No prescription is given without context. To begin, contact the Medical Concierge at contact@healthi-life.com or +66 91 999 1744, or request a consultation.
Precision interventions. Long-term strategies. No shortcuts.
- คะแนน Google 5.0 · 238 รีวิว
- ผู้รับบริการกว่า 2,500 คน
- จาก 50+ ประเทศ
- 2025 Regenerative Clinic of the Year in Asia-Pacific (คลินิกการแพทย์ฟื้นฟูแห่งปี 2025 ในเอเชียแปซิฟิก) — GlobalHealth Asia-Pacific Awards
Frequently Asked Questions
Related Resources
- Medical Weight Loss Bangkok: the hub page comparing all GLP-1 options and booking.
- Ozempic Bangkok: diabetes-branded semaglutide — not dispensed at Healthi Life.
- Wegovy Bangkok: semaglutide licensed for weight management — not dispensed at Healthi Life.
- Mounjaro Bangkok: tirzepatide, dual GIP/GLP-1 action.
- Retatrutide Bangkok: investigational triple-receptor program.
- Dr. Sarassawadee Suwanjinda (Dr. Petch): your supervising physician.
- Request a consultation: speak with the Medical Concierge.
Discuss a GLP-1 program with a physician
Book a consultation to review your eligibility, baseline labs, and the GLP-1 option best matched to your profile.
Book a ConsultationAbout the Author — Dr. Sarassawadee Suwanjinda (Dr. Petch), MD
Co-Founder · Chief Medical Officer, Healthi Life — Longevity & Functional Medicine (IBLM Diplomate · ISSCA · CBAM · AAAM Anti-Aging, Member)
Dr. Petch co-founded Healthi Life, the doctor-led longevity house in Ekkamai, Bangkok, and heads its biomarker-driven longevity programs, including physician-supervised GLP-1 weight loss. She designs and supervises each guest's metabolic plan with a diagnosis-first philosophy, and confirms a prescription only once the assessment supports it. Read more on her physician profile.
Medical disclaimer: This content is informational and reviewed by a Healthi Life physician. It does not constitute medical advice, diagnosis, or a binding offer. GLP-1 medications are prescription treatments delivered under physician supervision and require individual clinical assessment. Reported effects and outcomes vary between individuals and are not guaranteed. Always consult a qualified physician before starting any new treatment.
ตรวจทานทางการแพทย์โดย Dr. Petch
Dr. Petch — Diplomate คณะกรรมการเวชศาสตร์วิถีชีวิตนานาชาติ (IBLM)
ตรวจทานล่าสุด: 16 กรกฎาคม 2569
หน้านี้ให้ข้อมูลทั่วไป ไม่ถือเป็นคำแนะนำทางการแพทย์ การวินิจฉัย หรือการรักษา ผลลัพธ์ของแต่ละบุคคลอาจแตกต่างกัน GLP-1 medication (semaglutide — Ozempic, Wegovy; tirzepatide — Mounjaro) เป็นยาที่ต้องสั่งจ่ายโดยแพทย์ และให้การรักษาได้เฉพาะหลังการประเมินโดยแพทย์ผู้มีใบอนุญาตประกอบวิชาชีพเวชกรรม หน้านี้จัดทำขึ้นเพื่อให้ข้อมูลทางการแพทย์ ไม่ใช่การโฆษณาหรือการเสนอขายยาหรือบริการ ยาและเปปไทด์ทุกรายการที่ระบุในหน้านี้จ่ายให้เฉพาะหลังการปรึกษาแพทย์ที่ Healthi Life และตามใบสั่งแพทย์ ราคาที่เผยแพร่มีไว้เพื่อความโปร่งใส ไม่ใช่ข้อเสนอเพื่อจำหน่าย ควรปรึกษาแพทย์ผู้มีใบอนุญาตเกี่ยวกับอาการของคุณเสมอ ดูรายละเอียดได้ที่ ข้อสงวนสิทธิ์ทางการแพทย์ฉบับเต็ม.

Dr. Sarassawadee Suwanjinda (Dr. Petch)
แพทย์ที่ยืนยันตัวตนแล้วผู้ร่วมก่อตั้งและ Chief Medical Officer
International Board of Lifestyle Medicine (IBLM) Diplomate
พญ. สรัสวดี สุวรรณจินดา (พญ. เพชร) เป็นผู้ร่วมก่อตั้งและ Chief Medical Officer ของ Healthi Life และเป็น Diplomate คณะกรรมการเวชศาสตร์วิถีชีวิตนานาชาติ (IBLM) เธอดูแลโปรแกรมลองเจวิตี้ — โปรโตคอลที่ออกแบบจากอายุชีวภาพและไบโอมาร์กเกอร์ และตรวจวัดซ้ำเป็นระยะ
